N4P has announced the appointment of Ardena Holding NV (‘Ardena’) as its contract development and manufacturing organisation (‘CDMO’) partner for the technology transfer and upscaling manufacture of Nuvec®, the Group’s unique silica nanoparticle
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has announced that Nuvec® loaded with coronavirus plasmid has successfully transfected Human Embryonic Kidney (“HEK”) cells in vitro and induced an expression of the spike protein in the cells.
N4 Pharma PLC (N4P.L) Positive Covid-19 In Vitro Study Results
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that Nuvec® loaded with Coronavirus plasmid